{"text": "biib crl received for natalizumab in relapsing ms biogen biib provides regulatory update on the supplemental biologic license application sbla for subcutaneous administration of tysabri natalizumab"}
{"text": "biib gets crl from fda for application seeking approval of a subcutaneous formulation of ms drug tysabri"}
{"text": "biib biogen provides regulatory update on the supplemental biologic license application sbla for subcutaneous administration of tysabri natalizumab"}
{"text": "biib biogen provides regulatory update on the supplemental biologic license application sbla for subcutaneous administration of tysabri natalizumab"}
{"text": "biogen provides regulatory update on the supplemental biologic license application for subcutaneous administration of tysabri biib"}
{"text": "biib below avg volume daily appearances since 2010 287 close 5 days later avg 0 63 sd 10 88 worst 80 31 best 50 59 10 days later avg 1 15 sd 15 81 worst 84 75 best 65 00 30 days later avg 1 96 sd 26 75 worst 103 76 best 58 86"}
